Latest by Myles Helfand
HIV in plasma vs. rectal mucosa; engagement in care while on PrEP; depression and outcomes among women with HIV; dolutegravir resistance in the wake of monotherapy.
Reductions in erectile function among men who have sex with men; Australia, San Francisco, and 90-90-90 “fast track” targets; hepatitis C infection and HIV risk; safety of the live herpes zoster vaccine.
Stroke risk among underrepresented populations; the realism of UNAIDS 90-90-90 goals; HIV persistence and inflammation amidst long-term suppression; HDL cholesterol as a predictor of immune recovery.
How West Virginia is responding; a text-message based continuum-of-care intervention; PrEP and risk compensation; a link between inflammation, frailty, and cytomegalovirus infection.
Primary care + HIV care = improved health care engagement; the efficacy of different HIV testing and treatment interventions; abdominal fat and hypertension rates; the ethics of HIV phylogenetics.
Whether a local HIV outbreak in Tijuana, Mexico, may be related to police activity; PrEP and stigma in hookup apps; HIV, aging, and the immune system; cannabis as a systemic anti-inflammatory.
Long-term glucose disorders; anal vs. cervical HPV; PrEP adherence among U.S. veterans; economic incentives to spur HIV testing.
The effect of HIV treatment on HPV risk; bone mineral density declines in women vs. men; how hep C cure affects kidney function; when it comes to non-daily PrEP, location matters.
The risks of multiple non-HIV medication prescriptions; PrEP use and sexually transmitted infection incidence; how vaginal bacteria relate to HIV seroconversion; the effect of early treatment on HIV in the brain.
Gauging treatment priority when CD4 count is high; the effect of hepatitis C coinfection on response to HIV treatment; HIV, aging and comorbidity in Africa; PrEP and drug-resistant gonorrhea.